No products in the cart.
Popular
Essential Tremor Program
T-type Calcium Antagonists
Stage：PCC (Preclinical Candidate)
A new selective T-type calcium channel blocker targeting the core tremor-generating neural circuit, with mechanism validated by FDA Breakthrough Therapy Designation (BTD).
- FDA BTD validated mechanism
- First-in-class potential
- Addresses abuse risk of current therapies
- Novel mechanism targeting tremor circuits
Target Launch：License-in (China)
